Rilzabrutinib – Talk Bio

Actionable Insights Powered by AI

Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)

6 months ago talkbio0Tagged Autoimmune thrombocytopenia, BTK inhibitor, Clinical Research, Phase 3 Clinical Trials, Rilzabrutinib, sanofi

Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study

Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Clinical Trials, Drug Development, Drug Industry, Investments, Phase III, Principia, Rilzabrutinib, sanofi, strategic, Success

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.